Surveillance of adverse events following immunization with measles-containing vaccines in Shanghai， 2011-2018
10.19428/j.cnki.sjpm.2021.19620
- VernacularTitle:2011—2018年上海市含麻疹成分疫苗疑似预防接种异常反应监测分析
- Author:
Lin-lin WU
1
;
Jie-chen LIU
1
;
Zhi LI
1
;
Hui-yong SHAO
1
;
Xiang GUO
1
;
Xiao-dong SUN
1
Author Information
1. Shanghai Municipal Center for Disease Control and Prevention， Shanghai 200336， China
- Publication Type:Research Article
- Keywords:
measles containing vaccine;
adverse events following immunization;
safety;
surveillance
- From:
Shanghai Journal of Preventive Medicine
2021;33(4):291-295
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the safety of measles-containing vaccines （MCV） in Shanghai city. Methods:Adverse event following immunization cases related to measles attenuated live vaccine （MV）， measles and rubella combined attenuated live vaccine （MR） and measles， mumps and rubella combined attenuated live vaccine （MMR） vaccination in Shanghai during 2011—2018 were collected from the National AEFI Surveillance System for epidemiological analysis. Results:A total of 15 055 MVC-related AEFI cases were reported， for an incidence of 139.74 per 100 000 doses. Among all MVC-related AEFI cases， the male to female ratio was 1.17∶1， and 12 068 （111.70 per 100 000 doses） were common reactions， with 1 050 from MV（64.66 per 100 000）， 5 484 from MR（134.36 per 100 000）and 5 534 from MMR（108.60 per 100 000. Most of common reactions were fever （96.01 per 100 000）， but 2 939 （27.20 per 100 000） were rare reactions， with 408 from MV （25.12 per 100 000）， 1 983 from MR （48.59 per 100 000） and 548 from MMR （10.75 per 100 000）. Most of rare reactions were allergic rash （25.00 per 100 000）. Conclusion:MCV has a good safety profile but we should continue to strengthen MCV-related AEFI surveillance.
